T regulatory and T helper 17 cells in primary Sjögren's syndrome: Facts and perspectives

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Alunno, Alessia ^a   Carubbi, Francesco ^b   Bistoni, Onelia ^a   Caterbi, Sara ^a   Bartoloni, Elena ^a   Mirabelli, Giulia ^a   Cannarile, Francesca ^a   Cipriani, Paola ^b   Giacomelli, Roberto ^b   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

CD4+ T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE DURATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SALIVARY GLAND; SJOEGREN SYNDROME; TH17 CELL; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; HUMANS; INTERLEUKIN-23; INTERLEUKIN-6; INTERLEUKINS; SJOGREN'S SYNDROME; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84929347277     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/243723     Document Type: Review

References (91)

1. P. Brito-Zerón and M. Ramos-Casals, "Advances in the understanding and treatment of systemic complications in Sjögren's syndrome", Current Opinion in Rheumatology, vol. 26, no. 5, pp. 520-527, 2014.
2. G. Nocturne and X. Mariette, "Sjögren syndrome-associated lymphomas: an update on pathogenesis and management", The British Journal of Haematology, vol. 168, no. 3, pp. 317-327, 2015.
3. T. C. Adamson III, R. I. Fox, D. M. Frisman, and F. V. Howell, "Immunohistologic analysis of lymphoid infiltrates in primary Sjögren's syndrome using monoclonal antibodies", The Journal of Immunology, vol. 130, no. 1, pp. 203-208, 1983.
4. M. I. Christodoulou, E. K. Kapsogeorgou, and H. M. Moutsopoulos, "Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome", Journal of Autoimmunity, vol. 34, no. 4, pp. 400-407, 2010.
5. E. K. Kapsogeorgou, M. I. Christodoulou, D. B. Panagiotakos et al., "Minor salivary gland inflammatory lesions in Sjögren syndrome: do they evolve?" The Journal of Rheumatology, vol. 40, no. 9, pp. 1566-1571, 2013.
6. D. Zhou, Y.-T. Chen, F. Chen et al., "Critical involvement of macrophage infiltration in the development of Sjögren's syndrome-associated dry eye", The American Journal of Pathology, vol. 181, no. 3, pp. 753-760, 2012.
7. F. Carubbi, A. Alunno, P. Cipriani et al., "Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: a retrospective study", Seminars in Arthritis and Rheumatism, vol. 44, no. 3, pp. 314-324, 2014.
8. D. O. Gor, N. R. Rose, and N. S. Greenspan, "TH1-TH2: a procrustean paradigm", Nature Immunology, vol. 4, no. 6, pp. 503-505, 2003.
9. R. V. Luckheeram, R. Zhou, A. D. Verma, and B. Xia, "CD4+T cells: differentiation and functions", Clinical and Developmental Immunology, vol. 2012, Article ID 925135, 12 pages, 2012.
10. P. Miossec, T. Korn, and V. K. Kuchroo, "Interleukin-17 and type 17 helper T cells", The New England Journal of Medicine, vol. 361, no. 9, pp. 848-898, 2009.
11. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases", Journal of Immunology, vol. 155, no. 3, pp. 1151-1164, 1995.
12. K. G. Schmetterer, A. Neunkirchner, and W. F. Pickl, "Naturally occurring regulatory T cells: markers, mechanisms, andmanipulation", The FASEB Journal, vol. 26, no. 6, pp. 2253-2276, 2012.
13. L. Passerini, F. R. Santoni De Sio, M. G. Roncarolo, and R. Bacchetta, "Forkhead box P3: the peacekeeper of the immune system", International Reviews of Immunology, vol. 33, no. 2, pp. 129-145, 2014.
14. F. Ramsdell and S. F. Ziegler, "FOXP3 and scurfy: how it all began", Nature Reviews Immunology, vol. 14, no. 5, pp. 343-349, 2014.
15. M. Noack and P. Miossec, "Th17 and regulatory T cell balance in autoimmune and inflammatory diseases", Autoimmunity Reviews, vol. 13, no. 6, pp. 668-677, 2014.
16. M. D. Sharma, D.-Y. Hou, Y. Liu et al., "Indoleamine 2, 3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes", Blood, vol. 113, no. 24, pp. 6102-6111, 2009.
17. J.-E. Gottenberg, F. Lavie, K. Abbed et al., "CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome", Journal of Autoimmunity, vol. 24, no. 3, pp. 235-242, 2005.
18. X. Li, L. Qian, G. Wang et al., "T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren's syndrome", Journal of Rheumatology, vol. 34, no. 12, pp. 2438-2445, 2007.
19. M.-F. Liu, L.-H. Lin, C.-T. Weng, and M.-Y. Weng, "Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sjögren's syndrome", Lupus, vol. 17, no. 1, pp. 34-39, 2008.
20. M. Miyara, Z. Amoura, C. Parizot et al., "Global natural regulatory T cell depletion in active systemic lupus erythematosus", The Journal of Immunology, vol. 175, no. 12, pp. 8392-8400, 2005.
21. M. I. Christodoulou, E. K. Kapsogeorgou, N. M. Moutsopoulos, and H. M. Moutsopoulos, "Foxp3+ T-regulatory cells in Sjögren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors", The American Journal of Pathology, vol. 173, no. 5, pp. 1389-1396, 2008.
22. P. Szodoray, G. Papp, I. F. Horvath et al., "Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome", Clinical and Experimental Immunology, vol. 157, no. 3, pp. 343-349, 2009.
23. M. Sarigul, V. Yazisiz, C. I. Başsorgun et al., "The numbers of Foxp3+ Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren's syndrome", Lupus, vol. 19, no. 2, pp. 138-145, 2010.
24. L. Banica, A. Besliu, G. Pistol et al., "Quantification and molecular characterization of regulatory T cells in connective tissue diseases", Autoimmunity, vol. 42, no. 1, pp. 41-49, 2009.
25. J. Furuzawa-Carballeda, G. Hernández-Molina, G. Lima, Y. Rivera-Vicencio, K. Férez-Blando, and L. Llorente, "Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross-sectional study", Arthritis Research & Therapy, vol. 15, no. 3, article R68, 2013.
26. A. Alunno, M. G. Petrillo, G. Nocentini et al., "Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome", Rheumatology, vol. 52, no. 8, Article ID ket179, pp. 1387-1396, 2013.
27. A. Alunno, E. Bartoloni, O. Bistoni et al., "Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new", Clinical and Developmental Immunology, vol. 2012, Article ID823085, 5 pages, 2012.
28. F. A. H. Cooles, J. D. Isaacs, and A. E. Anderson, "Treg cells in rheumatoid arthritis: an update", Current Rheumatology Reports, vol. 15, no. 9, article 352, 2013.
29. N. E. Aerts, E. J. Dombrecht, D. G. Ebo, C. H. Bridts, W. J. Stevens, and L. S. De Clerck, "Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis", Cellular Immunology, vol. 251, no. 2, pp. 109-115, 2008.
30. G. M. Han, N. J. O'Neil-Andersen, R. B. Zurier, and D. A. Lawrence, "CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis", Cellular Immunology, vol. 253, no. 1-2, pp. 92-101, 2008.
31. M. Miyara and S. Sakaguchi, "Human FoxP3+ CD4+ regulatory T cells: their knowns and unknowns", Immunology & Cell Biology, vol. 89, no. 3, pp. 346-351, 2011.
32. M.-G. De Goër De Herve, E. Gonzales, H. Hendel-Chavez et al., "CD25 appears non essential for human peripheral T (reg) maintenance in vivo", PLoS ONE, vol. 5, no. 7, Article ID e11784, 2010.
33. B. Zhang, X. Zhang, F. L. Tang, L. P. Zhu, Y. Liu, and P. E. Lipsky, "Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus", Annals of the Rheumatic Diseases, vol. 67, no. 7, pp. 1037-1040, 2008.
34. H.-X. Yang, W. Zhang, L.-D. Zhao et al., "Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?" Arthritis Research & Therapy, vol. 11, no. 5, article R153, 2009.
35. M. G. Petrillo, S. Ronchetti, E. Ricci et al., "GITR+ regulatory T cells in the treatment of autoimmune diseases", Autoimmunity Reviews, vol. 14, no. 2, pp. 117-126, 2015.
36. R. Bianchini, O. Bistoni, A. Alunno et al., "CD4+CD25lowGITR+ cells: a novel human CD4+ T-cell population with regulatory activity", European Journal of Immunology, vol. 41, no. 8, pp. 2269-2278, 2011.
37. G. Nocentini, A. Alunno, M. G. Petrillo et al., "Expansion of regulatory GITR+CD25low/-CD4+ T cells in systemic lupus erythematosus patients", Arthritis Research & Therapy, vol. 16, no. 5, article 444, 2014.
38. J. M. R. Van Amelsfort, K. M. G. Jacobs, J. W. J. Bijlsma, F. P. J. G. Lafeber, and L. S. Taams, "CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid", Arthritis and Rheumatism, vol. 50, no. 9, pp. 2775-2785, 2004.
39. M. Möttönen, J. Heikkinen, L. Mustonen, P. Isomáki, R. Luukkainen, and O. Lassila, "CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis", Clinical and Experimental Immunology, vol. 140, no. 2, pp. 360-367, 2005.
40. C. Gu, L. Wu, and X. Li, "IL-17 family: cytokines, receptors and signaling", Cytokine, vol. 64, no. 2, pp. 477-485, 2013.
41. W. B. Van Den Berg and I. B. McInnes, "Th17 cells and IL-17 a focus on immunopathogenesis and immunotherapeutics", Seminars in Arthritis & Rheumatism, vol. 43, no. 2, pp. 158-170, 2013.
42. A. M. Lin, C. J. Rubin, R. Khandpur et al., "Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis", The Journal of Immunology, vol. 187, no. 1, pp. 490-500, 2011.
43. A. J. Hueber, D. L. Asquith, A. M. Miller et al., "Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium", The Journal of Immunology, vol. 184, no. 7, pp. 3336-3340, 2010.
44. E. V. Acosta-Rodriguez, L. Rivino, J. Geginat et al., "Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells", Nature Immunology, vol. 8, no. 6, pp. 639-646, 2007.
45. M. Mitsdoerffer, Y. Lee, A. Jáger et al., "Proinflammatory T helper type 17 cells are effective B-cell helpers", Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 32, pp. 14292-14297, 2010.
46. H.-C. Hsu, P. Yang, J. Wang et al., "Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice", Nature Immunology, vol. 9, no. 2, pp. 166-175, 2008.
47. G. Kuriya, T. Uchida, S. Akazawa et al., "Double deficiency in IL-17 and IFN-γ signalling significantly suppresses the development of diabetes in the NOD mouse", Diabetologia, vol. 56, no. 8, pp. 1773-1780, 2013.
48. X. Lin, K. Rui, J. Deng et al., "Th17 cells play a critical role in the development of experimental Sjögren's syndrome", Annals of the Rheumatic Diseases, 2014.
49. C. Q. Nguyen, H. Yin, B. H. Lee, W. C. Carcamo, J. A. Chiorini, and A. B. Peck, "Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirusmediated gene transfer", Arthritis Research & Therapy, vol. 12, no. 6, article R220, 2010.
50. C. Q. Nguyen, M. H. Hu, Y. Li, C. Stewart, and A. B. Peck, "Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice", Arthritis & Rheumatism, vol. 58, no. 3, pp. 734-743, 2008.
51. Y. Fei, W. Zhang, D. Lin et al., "Clinical parameter and Th17 related to lymphocytes infiltrating degree of labial salivary gland in primary Sjögren's syndrome", Clinical Rheumatology, vol. 33, no. 4, pp. 523-529, 2014.
52. G. E. Katsifis, S. Rekka, N. M. Moutsopoulos, S. Pillemer, and S. M. Wahl, "Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis", The American Journal of Pathology, vol. 175, no. 3, pp. 1167-1177, 2009.
53. K. Y. Kang, H. O. Kim, S.-K. Kwok et al., "Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands", Arthritis Research & Therapy, vol. 13, no. 5, article R179, 2011.
54. F. Ciccia, G. Guggino, A. Rizzo et al., "Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome", Annals of the Rheumatic Diseases, vol. 71, no. 2, pp. 295-301, 2012.
55. F. Ciccia, G. Guggino, A. Rizzo et al., "Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjogren's syndrome", Rheumatology, vol. 53, no. 7, pp. 1313-1320, 2014.
56. D. Mieliauskaite, I. Dumalakiene, R. Rugiene, and Z. MacKiewicz, "Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndrome", Clinical and Developmental Immunology, vol. 2012, Article ID 187258, 8 pages, 2012.
57. T. Maehara, M. Moriyama, J.-N. Hayashida et al., "Selective localization of T helper subsets in labial salivary glands from primary Sjögren's syndrome patients", Clinical and Experimental Immunology, vol. 169, no. 2, pp. 89-99, 2012.
58. A. Sakai, Y. Sugawara, T. Kuroishi, T. Sasano, and S. Sugawara, "Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18", The Journal of Immunology, vol. 181, no. 4, pp. 2898-2906, 2008.
59. S.-K. Kwok, M.-L. Cho, Y.-M. Her et al., "TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-κB pathway in patients with primary Sjogren's syndrome", Arthritis Research & Therapy, vol. 14, no. 2, article R64, 2012.
60. A. Alunno, O. Bistoni, E. Bartoloni et al., "IL-17-producing CD4-CD8. T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjögren's syndrome", Annals of the Rheumatic Diseases, vol. 72, no. 2, pp. 286-292, 2013.
61. A. Alunno, F. Carubbi, O. Bistoni et al., "CD4-CD8-T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement", Journal of Autoimmunity, vol. 51, pp. 38-43, 2014.
62. J. C. Crispín, M. Oukka, G. Bayliss et al., "Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys", The Journal of Immunology, vol. 181, no. 12, pp. 8761-8766, 2008.
63. E. Theander, L. Vasaitis, E. Baecklund et al., "Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome", Annals of the Rheumatic Diseases, vol. 70, no. 8, pp. 1363-1368, 2011.
64. K. Ohyama, M. Moriyama, J.-N. Hayashida et al., "Saliva as a potential tool for diagnosis of dry mouth including Sjögren's syndrome", Oral Diseases, vol. 21, no. 2, pp. 224-231, 2015.
65. M. H. Kang, M. K. Kim, H. J. Lee, H. I. Lee, W. R. Wee, and J. H. Lee, "Interleukin-17 in various ocular surface inflammatory diseases", Journal of Korean Medical Science, vol. 26, no. 7, pp. 938-944, 2011.
66. S. Y. Lee, S. J. Han, S. M. Nam et al., "Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients", The American Journal of Ophthalmology, vol. 156, no. 2, pp. 247-253, 2013.
67. X. Tan, S. Sun, Y. Liu et al., "Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome", Eye, vol. 28, no. 5, pp. 608-613, 2014.
68. J. K. Chung, M. K. Kim, and W. R. Wee, "Prognostic factors for the clinical severity of keratoconjunctivitis sicca in patientswith Sjögren's syndrome", British Journal of Ophthalmology, vol. 96, no. 2, pp. 240-245, 2012.
69. T. R. Reksten, M. V. Jonsson, E. A. Szyszko, J. G. Brun, R. Jonsson, and K. A. Brokstad, "Cytokine and autoantibody profiling related to histopathological features in primary Sjögren's syndrome", Rheumatology, vol. 48, no. 9, pp. 1102-1106, 2009.
70. A. Alunno, O. Bistoni, S. Caterbi, E. Bartoloni, G. Cafaro, and R. Gerli, "Serum interleukin-17 in primary Sjögren's syndrome: association with disease duration and parotid gland swelling", Clinical and Experimental Rheumatology, vol. 33, no. 1, p. 129, 2015.
71. A. Alunno, F. Carubbi, E. Bartoloni et al., "Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting?" Autoimmunity Reviews, vol. 13, no. 12, pp. 1167-1173, 2014.
72. M. Ramos-Casals, A. G. Tzioufas, J. H. Stone, A. Sisó, and X. Bosch, "Treatment of primary Sjögren syndrome: a systematic review", Journal of the American Medical Association, vol. 304, no. 4, pp. 452-460, 2010.
73. M. Ramos-Casals, P. Brito-Zerón, A. Sisó-Almirall, X. Bosch, and A. G. Tzioufas, "Topical and systemic medications for the treatment of primary Sjögren's syndrome", Nature Reviews Rheumatology, vol. 8, no. 7, pp. 399-411, 2012.
74. P. Brito-Zerón, A. Sisó-Almirall, A. Bové, B. A. Kostov, and M. Ramos-Casals, "Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions", Expert Opinion on Pharmacotherapy, vol. 14, no. 3, pp. 279-289, 2013.
75. A. Fazaa, T. Bourcier, E. Chatelus et al., "Classification criteria and treatment modalities in primary Sjögren's syndrome", Expert Review of Clinical Immunology, vol. 10, no. 4, pp. 543-551, 2014.
76. G. Mijnheer, B. J. Prakken, and F. Van Wijk, "The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics", Current Opinion in Rheumatology, vol. 25, no. 2, pp. 260-267, 2013.
77. P. C. Fox, M. Datiles, J. C. Atkinson et al., "Prednisone and piroxicam for treatment of primary Sjögren's syndrome", Clinical and Experimental Rheumatology, vol. 11, no. 2, pp. 149-156, 1993.
78. M. M. Zandbelt, F. H. J. Van Den Hoogen, P. C. De Wilde, P. J. S. Van Den Berg, H. G. F. Schneider, and L. B. A. Van De Putte, "Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatmentwith corticosteroids in Sjögren's syndrome", Annals of the Rheumatic Diseases, vol. 60, no. 5, pp. 511-513, 2001.
79. M. Edinger and P. Hoffmann, "Regulatory T cells in stem cell transplantation: strategies and first clinical experiences", Current Opinion in Immunology, vol. 23, no. 5, pp. 679-684, 2011.
80. M. E. Himmel, Y. Yao, P. C. Orban, T. S. Steiner, and M. K. Levings, "Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers", Immunology, vol. 136, no. 2, pp. 115-122, 2012.
81. M. Miyara, Y. Ito, and S. Sakaguchi, "TREG-cell therapies for autoimmune rheumatic diseases", Nature Reviews Rheumatology, vol. 10, no. 9, pp. 543-551, 2014.
82. D. V. Sawant and D. A. A. Vignali, "Once a Treg, always a Treg?" Immunological Reviews, vol. 259, no. 1, pp. 173-191, 2014.
83. P. Miossec and J. K. Kolls, "Targeting IL-17 and TH17 cells in chronic inflammation", Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763-776, 2012.
84. H. Sofen, S. Smith, R. T. Matheson et al., "Guselkumab (an IL-23-specific mAb) demonstrates clinical andmolecular response in patients withmoderate-to-severe psoriasis", Journal of Allergy and Clinical Immunology, vol. 133, no. 4, pp. 1032-1040, 2014.
85. F. Hua, G. M. Comer, L. Stockert et al., "Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study", The Journal of Clinical Pharmacology, vol. 54, no. 1, pp. 14-22, 2014.
86. J. Mélet, D. Mulleman, P. Goupille, B. Ribourtout, H. Watier, and G. Thibault, "Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response", Arthritis and Rheumatism, vol. 65, no. 11, pp. 2783-2790, 2013.
87. P. Eggleton, E. Bremer, J. M. Tarr et al., "Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects", Arthritis Research & Therapy, vol. 13, no. 6, article R208, 2011.
88. F. L. Van De Veerdonk, B. Lauwerys, R. J. Marijnissen et al., "The anti-CD20 antibody rituximab reduces the Th17 cell response", Arthritis and Rheumatism, vol. 63, no. 6, pp. 1507-1516, 2011.
89. F. Carubbi, A. Alunno, P. Cipriani et al., "Rituximab in primary Sjögren's syndrome: a ten-year journey", Lupus, vol. 23, no. 13, pp. 1337-1349, 2014.
90. L. A. Solt, N. Kumar, P. Nuhant et al., "Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand", Nature, vol. 472, no. 7344, pp. 491-494, 2011.
91. T. R. Reksten, S. J. A. Johnsen, M. V. Jonsson et al., "Genetic associations to germinal centre formation in primary Sjögren's syndrome", Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1253-1258, 2014.